Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 9Terminated 5Recruiting 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3Thoracic 1Other solid neoplasm 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Melanoma 8Leukemia, Myeloid, Acute 6Breast Neoplasms 6Colorectal Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Ovarian Neoplasms 4Neoplasm Metastasis 4Triple Negative Breast Neoplasms 3Skin Neoplasms 3Mesothelioma, Malignant 3Lymphoma, Non-Hodgkin 3Uveal Melanoma 2Uterine Cervical Neoplasms 2Stomach Neoplasms 2Sarcoma 2Recurrence 2Rectal Neoplasms 2Pleural Effusion, Malignant 2Neuroblastoma 2Neoplasms 2Multiple Myeloma 2Lung Neoplasms 2Leukemia, Myeloid 2Leukemia 2Head and Neck Neoplasms 2Glioblastoma 2Esophageal Neoplasms 2Carcinoma, Merkel Cell 2Urinary Bladder Neoplasms 1Turcot syndrome 1

Interventions

pembrolizumab 8Nivolumab 6Ipilimumab 6cemiplimab 4aldesleukin 3Interleukin-2 3Blood Specimen Collection 3fludarabine 2Specimen Handling 2HhAntag691 2Cyclophosphamide 2Biopsy 2trametinib 1spartalizumab 1sonidegib 1pertuzumab 1lifileucel 1four-arm poly(ethylene oxide)-b-poly(2-(diethylamino)ethyl methacrylate) 1fludarabine phosphate 1dabrafenib 1brodalumab 1atezolizumab 1Vitamin A 1Trastuzumab 1Tissue Banks 1Surgical Procedures, Operative 1Standard of Care 1Second Harmonic Generation Microscopy 1Resistance Training 1Red Light 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Skin Neoplasms × Interleukin-2 × Clear all
NCT04562129 2026-04-01

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Recruiting
29 enrolled
Dermatologic

Melanoma, Skin Neoplasms

NCT07288073 2026-02-13

TIL Therapy in cSCC and MCC

Dana-Farber Cancer Institute

Phase 2 Recruiting
14 enrolled
Dermatologic

Skin Neoplasms, Carcinoma, Merkel Cell

NCT05086692 2025-07-09

ABILITY-1

Medicenna Therapeutics, Inc.

Phase 1/2 Recruiting
115 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Mesothelioma, Malignant, Urinary Bladder Neoplasms, Carcinoma, Basal Cell, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Skin Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡